In a nutshell This study looked at the effect of radiotherapy after autologous stem cell transplantation for patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that patients had better tumor control when treated with involved-field radiotherapy after autologous stem cell transplantation. Some...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Lenalidomide in mantle cell lymphoma patients already treated with ibrutinib
In a nutshell This study examined the effectiveness of lenalidomide (Revlimid) in patients with mantle cell lymphoma (MCL) already treated with ibrutinib (Imbruvica). The authors concluded that lenalidomide was effective following ibrutinib. Some background There is no standard-of-care treatment for patients with relapsed or refractory (did not...
Read MoreUse of bortezomib plus rituximab to treat patients with relapsed follicular lymphoma
In a nutshell This study looked at the effectiveness of bortezomib plus rituximab for treating patients with relapsed follicular lymphoma. The study concluded that bortezomib plus rituximab is a safe and effective treatment for patients with relapsed follicular lymphoma. Some background Follicular lymphoma (FL) is a common type of...
Read MoreUpfront autologous stem cell transplantation treatment for patients with high-risk diffuse large B-cell lymphoma
In a nutshell This study looked at the effectiveness of autologous stem cell transplantation after their first remission for patients with high-risk diffuse large B-cell lymphoma. The study concluded that patients who received autologous stem cell transplantation had better outcomes than those who did not. Some background Diffuse large B-cell...
Read MoreReview of current treatments for mantle cell lymphoma
In a nutshell This is a review of the current standards of care for patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a relatively rare type of non-Hodgkin lymphoma. It is considered an incurable disease. Treatment type depends on many clinical factors, such as patient age, disease stage, and disease...
Read MoreDoes Alcohol Increase Cancer Risk?
In July 2017, the American Society of Clinical Oncology (ASCO) conducted the National Cancer Opinion Survey to find out what people in the US know about cancer. ASCO released the results in October. The findings have already influenced recommendations made by the organization. Beliefs About Cancer Risk Among other questions, the survey asked 4,016...
Read MoreNew Studies Linking Gut Bacteria and Cancer Treatment
In It’s All In Your Gut, A High Fiber Diet and the Immune System, we introduced the microbiome that lives in our body. It helps with our digestion and makes the short-chained fatty acids (SCFAs) that are important to our immune system. Now several recent studies are looking at bacteria in the bodies of people with cancer. Specifically, these...
Read MoreRituximab maintenance therapy for patients with follicular lymphoma
In a nutshell This study is a review of the effectiveness of rituximab maintenance therapy for patients with follicular lymphoma. The authors concluded rituximab maintenance improves survival outcomes for patients with follicular lymphoma. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is most commonly treated...
Read MoreThe use of bortezomib, cyclophosphamide, and rituximab to treat patients with relapsed mantle cell lymphoma
In a nutshell This study looked at the effectiveness of bortezomib plus cyclophosphamide and rituximab at treating patients with relapsed mantle cell lymphoma. The study concluded that this combination of medication is safe and effective at treating patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle...
Read MoreLenalidomide treatment for patients with relapsed diffuse large B-cell lymphoma
In a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...
Read MoreComparing health related quality of life between indolent non-Hodgkin lymphoma patients treated with obinutuzumab plus bendamustine vs bendamustine alone
In a nutshell This study compared the quality of life between indolent non-Hodgkin lymphoma patients who are treated with obinutuzumab plus bendamustine or bendamustine alone. The study concluded that patients treated with obinutuzumab plus bendamustine experience prolonged quality of life compared to patients treated with bendamustine...
Read MoreWar on Cancer: The Right Metaphor?
“For me, having lost my husband, it’s frustrating to hear publicly people saying to John McCain, ‘If anybody can beat this you can — you’re so tough.’ Not that it’s intentionally hurtful, but it does leave those of us who’ve lost a loved one thinking, ‘Was my loved one not tough enough? Did he not fight hard enough?'” ~Dannagal...
Read More
